# Table of Contents

1. The Limits of Risk and the Concept of the REMS................................. 1
3. When is a REMS needed? ................................................................. 17
5. Components of a REMS: Communication Plans and Implementation Systems... 33
6. Components of a REMS: Elements to Assure Safe Use (ETASU) ............ 35
7. Components of a REMS: REMS Assessment ..................................... 43
8. Anticipating, Preparing and Filing a REMS ........................................ 49
9. Modifying a REMS; Being Released From a REMS ......................... 59
10. REMS for Entire Drug Classes ......................................................... 65
11. REMS and the Opioid Crisis ............................................................ 71
12. REMS for Drugs for Use in Infants, Children and Adolescents ............ 79
13. Effect of a REMS on the Speed of Review and Approval of New Drugs..... 83
14. The Impact of REMS on Generic Drug Approvals and Drug Competition.... 87
15. Effects of the REMS Program on the Healthcare System and Pharmaceutical Competition................................................................. 95
16. The Evolving REMS Process ............................................................ 99
17. Guidance Documents and Databases on REMS ................................. 103

## Appendices

Appendix 1 ..................................................................................................... 109
Appendix 2 ..................................................................................................... 113
Appendix 3 ..................................................................................................... 119
Appendix 4 ..................................................................................................... 123

Index ............................................................................................................... 145

About the Author .......................................................................................... 157
Figures

Figure I-1. Evolution of Risk Management Plans for Drugs with a High-Risk Profile vi

Figure 1-1. Evolution of Formal Risk Management Plans for Drugs With a High-Risk Profile* 3

Figure 1-2. Basis for FDA’s Process of Determining Risk of a Drug 6

Figure 1-3. FDAAA-Mandated Advisory Committee Meeting 7

Figure 4-1. History of Medication Guides for Approved Products 26

Tables

Table 3-1. NDAs and BLAs With REMS Approved January 2017–May 2018 18

Table 3-2. Products Approved Before 25 March 2008 Deemed to Have a REMS 21

Table 6-1. ETASUs Approved Per Year 37

Table 8-1. REMS Components 49

Table 10-1. Shared System REMS 66

Table 12-1. Products With Pediatric Indications Approved by FDA, March 2008–September 2009 80

Table 16-1. Risk Minimization Tool Kit 101